Table 5.
Investigational drugs in phase II trials for treatment-resistant depression (2014 and later).
| Compound | Sponsor | Identifier | Primary outcome | Time frame | N a | Results or status |
|---|---|---|---|---|---|---|
| Glutamatergic agents | ||||||
| AVP-923 | James Murrough (NY, USA) | NCT01882829 | MADRSe | 10 W | 20 | March 2016b |
| AVP-786 | Avanir (USA) | NCT02153502 | MADRSe | 10 W | 200 | March 2016b |
| CERC-301 | Cerecor (USA) | Reference [84] | HDRS-17d | 5 W | 137 | NS |
| Cerecor (USA) | NCT02459236 | Bech-6f | 4 D | 104 | September 2016b | |
| AV-101 | National Institute of Mental Health (USA) | NCT02484456 | HDRSd | Multiple | 25 | December 2019b |
| AZD6765 | Astra-Zeneca (UK) | Reference [89] | MADRSe | Multiple | 22 | Small, transient effectj |
| Rapastinel | Allergan (USA) | NCT01684163 | HDRSd | 16 W | 369 | April 2014b |
| RO4995819 | Hoffmann-La Roche (Switzerland) | 2011–002160-24g | MADRSe | 6 W | 340 | Terminated |
| Other psychotropic drugs | ||||||
| Ziprasidone | Massachusetts General Hospital (USA) | Reference [96] | HDRSd | 8 W | 139 | ZIP = 35% PL = 20%c,i |
| Psilocybin | Imperial College London (UK) | Reference [100] | Psychedelic | PDEh | 12 | Ongoing |
| Somatic drugs | ||||||
| Minocycline | Charite University (Germany) | NCT02456948 | MADRSe | 6 W | 160 | February 2019b |
| Tocilizumab | Brigham and Women’s Hospital (USA) | NCT02660528 | HDRSd | 8 W | 15 | June 2017b |
| Sirukumab | Janssen-Cilag International (Poland) | 2014–005206-3g | HDRSd | 12 W | 192 | Ongoing |
a
Enrolment (final or estimated).
b
Primary completion date (past or estimated).
c
Statistically significant.
d
Hamilton Depression Rating Scale.
e
Montgomery–Asberg Depression Rating Scale.
f
6-item unidimensional subset of the HDRS-17.
g
Eudra identifier.
h
Peak drug effects.
i
Percent of responders (see text).
j
See text.
D: days; NS: non-statistically significant; PL: placebo; W: weeks; ZIP: Ziprasidone.